These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 18097234)

  • 1. HIV dynamics and immunosenescence.
    Getz WM
    AIDS; 2008 Jan; 22(2):307-9. PubMed ID: 18097234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling the influence of activation-induced apoptosis of CD4+ and CD8+ T-cells on the immune system response of a HIV-infected patient.
    Stan GB; Belmudes F; Fonteneau R; Zeggwagh F; Lefebvre MA; Michelet C; Ernst D
    IET Syst Biol; 2008 Mar; 2(2):94-102. PubMed ID: 18397120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Practical identifiability of HIV dynamics models.
    Guedj J; Thiébaut R; Commenges D
    Bull Math Biol; 2007 Nov; 69(8):2493-513. PubMed ID: 17557186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A delay-differential equation model of HIV related cancer-immune system dynamics.
    Foryś U; Poleszczuk J
    Math Biosci Eng; 2011 Apr; 8(2):627-41. PubMed ID: 21631150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oscillatory viral dynamics in a delayed HIV pathogenesis model.
    Wang Y; Zhou Y; Wu J; Heffernan J
    Math Biosci; 2009 Jun; 219(2):104-12. PubMed ID: 19327371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune impairment thresholds in HIV infection.
    Iwami S; Nakaoka S; Takeuchi Y; Miura Y; Miura T
    Immunol Lett; 2009 Apr; 123(2):149-54. PubMed ID: 19428563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral diversity limits immune diversity in asymptomatic phase of HIV infection.
    Iwami S; Nakaoka S; Takeuchi Y
    Theor Popul Biol; 2008 May; 73(3):332-41. PubMed ID: 18342352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
    Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
    AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune activation and inflammation in HIV-1 infection: causes and consequences.
    Appay V; Sauce D
    J Pathol; 2008 Jan; 214(2):231-41. PubMed ID: 18161758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-1 Tat protein: immunological facets of a transcriptional activator.
    Gupta S; Mitra D
    Indian J Biochem Biophys; 2007 Oct; 44(5):269-75. PubMed ID: 18341200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of immune parameters before treatment interruption (TI) for CD4+ T-cell count change during TI in HIV infection.
    Huang KH; Loutfy MR; Boulet S; Toma E; Tsoukas CM; Bernard NF
    Antivir Ther; 2009; 14(3):381-92. PubMed ID: 19474472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response.
    Zanchetta M; Anselmi A; Vendrame D; Rampon O; Giaquinto C; Mazza A; Accapezzato D; Barnaba V; De Rossi A
    Antivir Ther; 2008; 13(1):47-55. PubMed ID: 18389898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parameter identifiability and estimation of HIV/AIDS dynamic models.
    Wu H; Zhu H; Miao H; Perelson AS
    Bull Math Biol; 2008 Apr; 70(3):785-99. PubMed ID: 18247096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On modeling the effects of T-cell vaccines on HIV acquisition and disease.
    Wick WD
    Stat Med; 2008 Oct; 27(23):4805-16. PubMed ID: 18265425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth rates in epidemic models: application to a model for HIV/AIDS progression.
    Gran JM; Wasmuth L; Amundsen EJ; Lindqvist BH; Aalen OO
    Stat Med; 2008 Oct; 27(23):4817-34. PubMed ID: 18288789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Linking Nef with the immunological and virological determinants of AIDS].
    Gómez-Icazbalceta G; Larralde C
    Rev Invest Clin; 2009; 61(3):243-51. PubMed ID: 19736813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Premature immunosenescence in HIV-infected patients on highly active antiretroviral therapy with low-level CD4 T cell repopulation.
    Molina-Pinelo S; Vallejo A; Díaz L; Soriano-Sarabia N; Ferrando-Martínez S; Resino S; Muñoz-Fernández MA; Leal M
    J Antimicrob Chemother; 2009 Sep; 64(3):579-88. PubMed ID: 19608579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tight regulation of the Epstein-Barr virus setpoint: interindividual differences in Epstein-Barr virus DNA load are conserved after HIV infection.
    Piriou E; van Dort K; Otto S; van Oers MH; van Baarle D
    Clin Infect Dis; 2008 Jan; 46(2):313-6. PubMed ID: 18171268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The frequency, activation, and coreceptor expression of lymphocytes in human immunodeficiency virus/hepatitis C virus co-infected patients in China.
    Shi W; Zhang Z; Zhang M; Liu J; Jiang Y; Wang Y; Jin X; Han X; Shang H
    Jpn J Infect Dis; 2009 Jul; 62(4):284-8. PubMed ID: 19628906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.